BioCryst Pharmaceuticals has initiated a Phase IIb study of BCX4208 as an add-on therapy in patients with gout who have not responded to allopurinol therapy alone.
BCX4208 is a next-generation purine nucleoside phosphorylase inhibitor, which has the potential to address unmet medical needs across a broad range of inflammatory and autoimmune diseases.
The randomised and double-blind dose-response study is designed to assess the safety and efficacy of BCX4208 in combination with allopurinol in patients who have not reached the serum uric acid (sUA) objective of <6 mg/dL following treatment with allopurinol 300 mg alone.
The primary endpoint of the study will be the proportion of subjects with sUA lover than 6 mg/dL at day 85.
The study will enrol 250 patients and will evaluate BCX4208 at doses of 5mg, 10mg, 20mg, 40mg and placebo, administered once-daily for 12 weeks, in combination with allopurinol’s standard dose of 300 mg.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData